Lilly Partnership TVM's Lilly backed project focused company model provides a direct channel to source and finance first in class assets, creating a compelling value proposition for early stage biotechs seeking strategic backing. This presents a business development path to engage high potential startups and offer not only capital but access to strategic partnerships with Lilly and a transatlantic investor network.

Cross Border Advantage With a transatlantic footprint spanning North America and Europe, TVM helps portfolio companies access global markets, regulatory guidance, and cross border partnering. Use this to target US and EU startups looking to scale with strategic investment and to introduce them to potential co investors and licensing opportunities with pharmaceutical partners.

AI Health Tech TVM has demonstrated interest in AI based and digital health assets including Vektor Medical and elderly care apps. This signals a favorable market focus for startups in AI driven diagnostics or remote patient monitoring seeking growth capital and strategic partnerships, including licensing deals and pilot collaborations with hospitals.

Investor Network Opportunity The firm manages about 900 million in assets with a small team, indicating strong deal appetite and potential for co investment syndication with other venture funds and LPs. This offers sales opportunities to connect fund managers and limited partners for co financing rounds, co lead roles, and cross fund partnerships.

Portfolio Acceleration TVM offers more than capital, including strategic advisory and potential post investment support to accelerate licensing, regulatory approvals, and exit strategies for portfolio companies. This position is attractive to startups seeking hands on help to accelerate milestones and to buyers or licensees looking for ready to partner assets.